QurAlis to Present Data From its Phase 1 Clinical Trial of QRL-101, a Potential Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener, at American Epilepsy Society 2025 Annual Meeting QurAlis ...
ATLANTA — Epilepsy experts are getting a better picture of the long-term safety and efficacy of azetukalner, a novel and potent Kv7 potassium channel opener, in patients with treatment-resistant focal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results